158 research outputs found
Children referred with lennox-gastaut syndrome in the Western Cape of South Africa
Introduction/Purpose: Lennox-Gastaut Syndrome (LGS) is one of the most common refractory epilepsies of childhood with significant morbidity and mortality. However there is paucity of data of this syndrome in resource limited settings (RLS). We sought to delineate the phenomenology, diagnosis, aetiologies, management and outcomes of children referred with LGS in the Western Cape Province of South Africa. To further identify early clinical markers differentiating LGS from other types of epilepsy. Methods. This retrospective observational cohort study included all children between 1 to < 18 years of age in the neurology database with a referral label of LGS between 2000-2018. The group were critiqued for those who met the diagnostic criteria of LGS. Then were categorized into those with confirmed LGS and remainder were not- LGS. Data of the social demographics, age of seizure onset, etiology, preceding epileptic spasms, and semiology of epilepsy types, management interventions were reviewed to identify key diagnostic indicators to permit early and targeted interventions for children with this epilepsy syndrome. Results; Of 2551 children managed with epilepsy, 110 were suspected at presentation to have LGS of these 66 records were available for assessment. The median (IQR) age in months at presentation was 35(16.0-54.5) with a slight male (37/66) predominance. 43(65%) met the criteria LGS and 23(35%) were not-LGS. 34(52%) had no identifiable cause for their epilepsy whilst a structural and metabolic cause were identified in 25(38%) and 3(5%) respectively. Moderate or severe cognitive impairment was associated with LGS (OR 2.59, p = 0.02 and OR =3.15, p = 0.01) and so were tonic seizures (OR=4.03, p=0.04). The most common diagnoses in the not-LGS group were other types of DEE not meeting the LGS criteria (15%) and uncategorised epileptic syndromes 11%. Conclusion; Over third of the children in this cohort were erroneously referred with LGS early in their course. This has implications for their management and prognostic counselling. Identification of indicators such as tonic seizures and moderate or severe intellectual/cognitive impairment are useful early markers which support a diagnosis of LGS and could be viable for use in our setting
Viral Diversity and Diversification of Major Non-Structural Genes vif, vpr, vpu, tat exon 1 and rev exon 1 during Primary HIV-1 Subtype C Infection
To assess the level of intra-patient diversity and evolution of HIV-1C non-structural genes in primary infection, viral quasispecies obtained by single genome amplification (SGA) at multiple sampling timepoints up to 500 days post-seroconversion (p/s) were analyzed. The mean intra-patient diversity was 0.11% (95% CI; 0.02 to 0.20) for vif, 0.23% (95% CI; 0.08 to 0.38) for vpr, 0.35% (95% CI; −0.05 to 0.75) for vpu, 0.18% (95% CI; 0.01 to 0.35) for tat exon 1 and 0.30% (95% CI; 0.02 to 0.58) for rev exon 1 during the time period 0 to 90 days p/s. The intra-patient diversity increased gradually in all non-structural genes over the first year of HIV-1 infection, which was evident from the vif mean intra-patient diversity of 0.46% (95% CI; 0.28 to 0.64), vpr 0.44% (95% CI; 0.24 to 0.64), vpu 0.84% (95% CI; 0.55 to 1.13), tat exon 1 0.35% (95% CI; 0.14 to 0.56 ) and rev exon 1 0.42% (95% CI; 0.18 to 0.66) during the time period of 181 to 500 days p/s. There was a statistically significant increase in viral diversity for vif (p = 0.013) and vpu (p = 0.002). No associations between levels of viral diversity within the non-structural genes and HIV-1 RNA load during primary infection were found. The study details the dynamics of the non-structural viral genes during the early stages of HIV-1C infection
Recommended from our members
Prevalence and molecular characterization of Hepatitis B in HIV infected individuals in Botswana
Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland
Objective: To assess factors at the start of antiretroviral therapy (ART) associated with long-term virological response in children.
Design: Multicentre national cohort.
Methods: Factors associated with viral load below 400 copies/ml by 12 months and virologic failure among children starting 3/4-drug ART in the UK/Irish Collaborative HIV Paediatric Study were assessed using Poisson models.
Results: Nine hundred and ninety-seven children started ART at a median age of 7.7 years (inter-quartile range 2.9–11.7), 251 (25%) below 3 years: 411 (41%) with efavirenz and two nucleoside reverse transcriptase inhibitors (EFVþ2NRTIs), 264 (26%) with nevirapine and two NRTIs (NVPþ2NRTIs), 119 (12%; 106 NVP, 13 EFV) with non-nucleoside reverse transcriptase inhibitor and three NRTIs (NNRTIþ3NRTIs), and 203 (20%) with boosted protease inhibitor-based regimens. Median follow-up after ART initiation was 5.7 (3.0–8.8) years. Viral load was less than 400 copies/ml by 12 months in 92% [95% confidence interval (CI) 91–94%] of the children. Time to suppression was similar across regimens (P¼0.10), but faster over calendar time, with older age and lower baseline viral load. Three hundred and thirtynine (34%) children experienced virological failure. Although progression to failure varied by regimen (P<0.001) and was fastest for NVPþ2NRTIs regimens, risk after 2 years on therapy was similar for EFVþ2NRTIs and NVPþ2NRTIs, and lowest for NNRTIþ3NRTIs regimens (P-interaction¼0.03). Older age, earlier calendar periods and maternal ART exposure were associated with increased failure risk. Early treatment discontinuation for toxicity occurred more frequently for NVP-based regimens, but 5-year cumulative incidence was similar: 6.1% (95% CI 3.9–8.9%) NVP, 8.3% (95% CI 5.6–11.6) EFV, and 9.8% (95% CI 5.7–15.3%) protease inhibitor-based regimens (P¼0.48).
Conclusion: Viral load suppression by 12 months was high with all regimens. NVPþ3NRTIs regimens were particularly efficacious in the longer term and may be a good alternative to protease inhibitor-based ART in young children
Recommended from our members
tat Exon 1 Exhibits Functional Diversity during HIV-1 Subtype C Primary Infection
Human immunodeficiency virus type 1 (HIV-1) Tat is a mediator of viral transcription and is involved in the control of virus replication. However, associations between HIV-1 Tat diversity and functional effects during primary HIV-1 infection are still unclear. We estimated selection pressures in tat exon 1 using the mixed-effects model of evolution with 672 viral sequences generated from 20 patients infected with HIV-1 subtype C (HIV-1C) over 500 days postseroconversion. tat exon 1 residues 3, 4, 21, 24, 29, 39, and 68 were under positive selection, and we established that specific amino acid signature patterns were apparent in primary HIV-1C infection compared with chronic infection. We assessed the impact of these mutations on long terminal repeat (LTR) activity and found that Tat activity was negatively affected by the Ala21 substitution identified in 13/20 (65%) of patients, which reduced LTR activity by 88% (±1%) (P < 0.001). The greatest increase in Tat activity was seen with the Gln35/Lys39 double mutant that resulted in an additional 49% (±14%) production of LTR-driven luciferase (P = 0.012). There was a moderate positive correlation between Tat-mediated LTR activity and HIV-1 RNA in plasma (P = 0.026; r = 0.400) after 180 days postseroconversion that was reduced by 500 days postseroconversion (P = 0.043; r = 0.266). Although Tat activation of the LTR is not a strong predictor of these clinical variables, there are significant linear relationships between Tat transactivation and patients' plasma viral loads and CD4 counts, highlighting the complex interplay between Tat mutations in early HIV-1C infection
- …